IMA-107 C-11

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C25H28FN7O
Molecular Weight	460.5353
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=NC2=C(C=CC=C2)N=C1C3=NN4C(=C3)N=C(C=C4N([11CH3])C5CCOCC5)N6CC[C@@H](F)C6

InChI

InChIKey=XJHYZPHNGDXRJW-PIMHITSUSA-N

InChI=1S/C25H28FN7O/c1-16-25(28-20-6-4-3-5-19(20)27-16)21-13-23-29-22(32-10-7-17(26)15-32)14-24(33(23)30-21)31(2)18-8-11-34-12-9-18/h3-6,13-14,17-18H,7-12,15H2,1-2H3/t17-/m1/s1/i2-1

HIDE SMILES / InChI

Molecular Formula	C25H28FN7O
Molecular Weight	460.5353
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Tue Apr 01 18:05:04 GMT 2025` Edited by `admin` on `Tue Apr 01 18:05:04 GMT 2025`
Record UNII	EUS54KI9L5
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

(11C)IMA-107

Preferred Name

English

IMA-107 C-11

Code

English

5-((3R)-3-FLUOROPYRROLIDIN-1-YL)-N-(11C)METHYL-2-(3-METHYLQUINOXALIN-2-YL)-N-TETRAHYDROPYRAN-4-YL-PYRAZOLO(1,5-A)PYRIMIDIN-7-AMINE

Systematic Name

English

Code System Code Type Description

PUBCHEM

118727099

Created by admin on Tue Apr 01 18:05:04 GMT 2025 , Edited by admin on Tue Apr 01 18:05:04 GMT 2025

PRIMARY

FDA UNII

EUS54KI9L5

Created by admin on Tue Apr 01 18:05:04 GMT 2025 , Edited by admin on Tue Apr 01 18:05:04 GMT 2025

PRIMARY

CAS

1810802-70-0

Created by admin on Tue Apr 01 18:05:04 GMT 2025 , Edited by admin on Tue Apr 01 18:05:04 GMT 2025

PRIMARY

Related Record Type Details


					1R38R691S2

CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A

TARGET->RADIOLIGAND

Interaction Type:

BINDING

Qualification:

IC50

Amount:


					7RCA4Q6HYZ

IMA-107

NON-LABELED -> LABELED

Related Record Type Details


					EUS54KI9L5

IMA-107 C-11

ACTIVE MOIETY

Comments:

Results: PET images and TACs showed regional heterogeneity, reflective of the known distribution of PDE10A. Kinetic modelling showed the superiority of the 2TC over the 1TC model (assessed visually and via AIC). SRTM also produced acceptable model fits. 2TC fits produced well-determined VT estimates (COV<10%) for 89/91 TACs. SRTM fits produced well-determined BPND estimates (COV<10%) for 85/91 TACs (remaining 6/91 all SN, all COV<20%). Time stability analysis supported a reduction in scan duration to 60 min. Inter-subject variability was good, with mean COV (n=7) for baseline scans of VT2TC: 21%, BPND2TC: 21%, BPNDSRTM: 18%. Test-retest variability (n=4) was VT2TC: 12%, BPND2TC: 15%, BPNDSRTM: 12%. There was an excellent correlation between the 2TC- and SRTM-derived BPND (r2>0.99 p<<0.05). Conclusions: Kinetic parameters for (11C)-IMA107 are well-estimated using 2TC and SRTM. Further studies will fully validate the use of cerebellum as reference region.